An immunometabolic signature of major depressive disorder in systemic lupus erythematosus - PubMed
3 hours ago
- #major depressive disorder
- #systemic lupus erythematosus
- #immunometabolic
- Major depressive disorder in systemic lupus erythematosus (SLEMDD) is the most frequent neuropsychiatric manifestation of SLE.
- SLEMDD patients show distinct immune profiles, including decreased naïve CD4+ T cells and naïve regulatory T cells (Tregs), and increased ICOS+ effector memory Tregs.
- Gut microbiota diversity is reduced in SLEMDD, with depletion of Akkermansia muciniphila and enrichment of Faecalibacterium prausnitzii.
- Metabolomic disruptions in SLEMDD include alterations in kynurenine and short-chain fatty acid pathways, such as decreased butyrate levels.
- Integrative analyses link Treg activation, microbial metabolites, and immune pathways, distinguishing SLEMDD from non-MDD SLE with high accuracy.
- The findings suggest potential for immunoregulatory or microbiota-targeted therapies in SLEMDD.